Pathology: hepatocell cancer (HCC); mHCC - (neo)adjuvant (NA); mHCC - 1st line (L1); mHCC - 2nd line (L2);
| hepatocell cancer (HCC) | mHCC - (neo)adjuvant (NA) | mHCC - 1st line (L1) | mHCC - 2nd line (L2) | ||||||||||||||
| Wang, 2024 | IMbrave050, 2023 | NCI-2018-01106, 2022 | Wang, 2024 | IMbrave-150, 2020 | COSMIC-312, 2023 | CARES-310, 2023 | EMERALD-1, 2024 | HIMALAYA, 2022 | CheckMate 459, 2019 | CheckMate 9DW, 2024 | LEAP 002, 2023 | ORIENT-32, 2021 | RATIONALE 301, 2024 | KEYNOTE-240, 2020 | KEYNOTE-394, 2022 | ||
| sintilimab | 3 | T1 | T1 | T1 | |||||||||||||
| atezolizumab plus bevacizumab | 2 | T1 | T1 | ||||||||||||||
| pembrolizumab alone | 2 | T1 | T1 | ||||||||||||||
| durvalumab plus bevacizumab | 1 | T1 | |||||||||||||||
| nivolumab plus ipilimumab plus SoC | 1 | T1 | |||||||||||||||
| Tislelizumab | 1 | T1 | |||||||||||||||
| atezolizumab plus cabozantinib | 1 | T1 | |||||||||||||||
| camrelizumab based treatment | 1 | T1 | |||||||||||||||
| pembrolizumab plus lenvatinib | 1 | T1 | |||||||||||||||
| nivolumab plus ipilimumab | 1 | T1 | |||||||||||||||
| durvalumab plus tremelimumab | 1 | T1 | |||||||||||||||
| nivolumab alone | 1 | T0 | T1 | ||||||||||||||
| VEGF(R) inhibitor | 0 | T0 | |||||||||||||||
| Standard of Care (SoC) | 0 | T0 | T0 | T0 | |||||||||||||
| lenvatinib | 0 | T0 | |||||||||||||||
| sorafenib | 0 | T0 | T0 | T0 | T0 | T0 | T0 | T0 | |||||||||
| placebo | 0 | T0 | T0 | T0 | |||||||||||||